Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
| ▸ | CA5A | P35218 | 6/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA7 | P43166 | 4/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206939 | 0.93 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL26206487 | 0.93 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL26206491 | 0.93 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL24916992 | 0.92 | TMPRSS2 (0.43) | TMPRSS2PYGLLMNATHRBSMN1; SMN2 | |
| SCHEMBL24606259 | 0.92 | TMPRSS2 (0.37) | TMPRSS2PYGLLMNATHRBSMN1; SMN2 | |
| SCHEMBL31536834 | 0.91 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL26206307 | 0.91 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL31536832 | 0.91 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL31536833 | 0.91 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL26206257 | 0.91 | TMPRSS2 (0.36) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297226-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240317754-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-26 | — | — | US | disclosed |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4424372-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4204421-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11926645-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023239665-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2 | GILEAD SCIENCES, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4204421-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022142477-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-07-07 | — | — | WO | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2021213288-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | 中国科学院上海药物研究所 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885PYGL 59/4885LMNA 1187/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885PYGL 59/4885LMNA 1187/4885 |
| US-20240317754-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | PNP, MTAP, NSUN2 | TMPRSS2 69/4885PYGL 1072/4885LMNA 1552/4885 |
| US-12297226-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885PYGL 59/4885LMNA 1187/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885PYGL 59/4885LMNA 1187/4885 |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885PYGL 59/4885LMNA 1187/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | TMPRSS2 145/4885PYGL 308/4885LMNA 923/4885 |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885PYGL 377/4885LMNA 205/4885 |
| US-11926645-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885PYGL 59/4885LMNA 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.